ArticleMolecular therapy. Oncology2026

FOXM1 drives cisplatin resistance in ovarian cancer through STIM1-mediated SOCE and STAT1 activation.

Tzu-Chien Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.